The Importance of Clinical Trial and Treatment Accessibility for Myeloma

At the 2024 ASH Annual Meeting, Marco Ruella, MD, an assistant professor of Hematology-Oncology, and colleagues presented findings from an analysis of treatment access and outcomes in minority health populations receiving commercial CAR T-cell therapy for multiple myeloma.